Onconova Therapeutics to Provide Corporate Update and Full Year 2020 Financial Results
March 04 2021 - 04:15PM
Onconova Therapeutics, Inc. (NASDAQ: ONTX), a clinical-stage
biopharmaceutical company focused on discovering and developing
novel products for patients with cancer, today announced that the
Company will release its year-end 2020 financial results on
Thursday, March 11, 2021, after the market closes. Management will
host a conference call and live webcast at 4:30 p.m. ET on the same
day to discuss these results and provide an update on its pipeline
programs.
Interested parties who wish to participate in
the conference call may do so by dialing (855) 428-5741 for
domestic and (210) 229-8823 for international callers and using
conference ID 3863774. Those interested in listening to the
conference call live via the internet may do so by visiting the
investors’ page of the company's website at www.onconova.com and
clicking on the webcast link.
A webcast replay will be available on the
Onconova website for 90 days following the call by visiting the
investor page of the company's website at www.onconova.com
About Onconova Therapeutics,
Inc. Onconova Therapeutics is a clinical-stage
biopharmaceutical company focused on discovering and developing
novel products to treat cancer. The Company has proprietary
targeted anti-cancer agents designed to disrupt specific cellular
pathways that are important for cancer cell proliferation.
Onconova’s novel, proprietary multi-kinase
inhibitor ON 123300 is planned to begin a dose-escalation and
expansion Phase 1 trial in the U.S. in the first half of 2021, and
a dose-escalation and expansion Phase 1 trial is currently underway
in China.
Onconova’s product candidate oral rigosertib is
currently in a dose-escalation and expansion Phase 1
investigator-initiated study targeting patients with KRAS+ lung
adenocarcinoma in combination with nivolumab. In addition, Onconova
has commenced preclinical work investigating rigosertib in
COVID-19.
For more information, please visit
www.onconova.com.
Contact information
Company Contact:Avi OlerOnconova Therapeutics,
Inc.267-759-3680ir@onconova.us https://www.onconova.com/contact/
Investor Contact:LHA Investor RelationsKim
Sutton Golodetz212-838-3777kgolodetz@lhai.com
Onconova Therapeutics (NASDAQ:ONTX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Onconova Therapeutics (NASDAQ:ONTX)
Historical Stock Chart
From Mar 2023 to Mar 2024